--- title: "Dianthus Therapeutics (DNTH) news: offering" url: "https://aibio.space/companies/dianthus-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "DNTH offering news: Dianthus launches $400,000,000 stock offering, then prices it at $81.00 a share. Dianthus Therapeutics, Inc." --- DNTH Dianthus Therapeutics, Inc. NASDAQ · United States # Dianthus Therapeutics (DNTH) news DNTH offering news Financings · 2026-03-09 ## [Dianthus launches $400,000,000 stock offering, then prices it at $81.00 a share](https://aibio.space/news/dianthus-launches-400-000-000-stock-offering-then-prices-81-00-share/) Dianthus priced 7,313,582 shares and pre-funded warrants for 402,468 shares at $81.00, for $624,999,648 in total, after launching a $400,000,000 offering. Its 2025 net loss was $162.3 million, and the supplement names no counsel. ## Latest Dianthus Therapeutics news We have not published a story on Dianthus Therapeutics yet. When there is news, it will appear here. ## Dianthus Therapeutics at a glance - **Ticker**: DNTH - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $886.8 million ### Related companies - [Scholar Rock Holding](https://aibio.space/companies/scholar-rock/) NASDAQ: SRRK - [Black Diamond Therapeutics](https://aibio.space/companies/black-diamond-therapeutics/) NASDAQ: BDTX - [PepGen](https://aibio.space/companies/pepgen/) NASDAQ: PEPG - [Alector](https://aibio.space/companies/alector/) NASDAQ: ALEC - [ViaDerma](https://aibio.space/companies/viaderma/) OTC: VDRM - [Aptevo Therapeutics](https://aibio.space/companies/aptevo-therapeutics/) NASDAQ: APVO - [REBUS HLDGS INC.](https://aibio.space/companies/rebus-hldgs/) OTC: RBSH - [Cognition Therapeutics](https://aibio.space/companies/cognition-therapeutics/) NASDAQ: CGTX ### Also on NASDAQ - [vTv Therapeutics](https://aibio.space/companies/vtv-therapeutics/) VTVT - [AbCellera Biologics](https://aibio.space/companies/abcellera-biologics/) ABCL - [Iovance Biotherapeutics](https://aibio.space/companies/iovance-biotherapeutics/) IOVA - [Bicara Therapeutics](https://aibio.space/companies/bicara-therapeutics/) BCAX - [SANUWAVE Health](https://aibio.space/companies/sanuwave-health/) SNWV - [HARVARD BIOSCIENCE INC](https://aibio.space/companies/harvard-bioscience/) HBIO ## Dianthus Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$2.0 million](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/) | [$6.2 million](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/) | | Research and development | [$145.6 million](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/) | [$83.1 million](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/) | | Net income (loss) | [-$162.3 million](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/) | [-$85.0 million](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/) | | Cash from operations | [-$129.1 million](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/) | [-$78.2 million](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/) | | Cash and equivalents | [$51.1 million](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000034/) | [$22.8 million](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/) | | Short-term investments | [$353.2 million](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000034/) | [$252.4 million](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $110.5 million, plus short-term investments of $776.3 million, $886.8 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Dianthus Therapeutics Has Dianthus Therapeutics raised money recently? Our latest story on this, dated Mar 9, 2026: "Dianthus launches $400,000,000 stock offering, then prices it at $81.00 a share". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/dianthus-launches-400-000-000-stock-offering-then-prices-81-00-share/). What is the ticker symbol of Dianthus Therapeutics? Dianthus Therapeutics, Inc. trades under the ticker DNTH on NASDAQ. Where is Dianthus Therapeutics listed? Dianthus Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: DUS:87E; FWB:87E; GETTEX:87E; LSX:A3ERZ4; MUN:87E; SWB:87E; TRADEGATE:87E; XETR:87E. What is the SEC CIK of Dianthus Therapeutics? The SEC Central Index Key (CIK) for Dianthus Therapeutics, Inc. is 1690585. Its filings are on SEC EDGAR. How many shares does Dianthus Therapeutics have outstanding? 55,934,378 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-04. Which country or territory is Dianthus Therapeutics listed under? Our directory records Dianthus Therapeutics, Inc. under United States. What does Dianthus Therapeutics do? Our directory classifies Dianthus Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Dianthus Therapeutics? The ISIN recorded for Dianthus Therapeutics, Inc. is US2528281080. Does aibio.space cover Dianthus Therapeutics? aibio.space lists Dianthus Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Dianthus Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What was Dianthus Therapeutics's revenue last year? $2.0 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Dianthus Therapeutics profitable? Dianthus Therapeutics, Inc. reported a net loss of $162.3 million for the fiscal year ended Dec 31, 2025, and used $129.1 million of cash in operations, per its annual report to the SEC. How much does Dianthus Therapeutics spend on research and development? $145.6 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Dianthus Therapeutics have? $886.8 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Dianthus Therapeutics (DNTH) stock news? Our latest story on Dianthus Therapeutics, dated Mar 9, 2026: "Dianthus launches $400,000,000 stock offering, then prices it at $81.00 a share". Dianthus priced 7,313,582 shares and pre-funded warrants for 402,468 shares at $81.00, for $624,999,648 in total, after launching a $400,000,000 offering. Its 2025 net loss was $162.3 million, and the supplement names no counsel. [Source](https://aibio.space/news/dianthus-launches-400-000-000-stock-offering-then-prices-81-00-share/). ## Investor discussion: Dianthus Therapeutics Members talk about Dianthus Therapeutics (DNTH). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Dianthus Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-03-09 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1690585/000119312526098846/d112823d424b5.htm) 2. 2025-09-08 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1690585/000119312525198345/d12425d424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:DNTH on TradingView](https://www.tradingview.com/symbols/NASDAQ-DNTH/). ## SEC filings and registration - **SEC name**: Dianthus Therapeutics, Inc. /DE/ - **CIK**: 1690585 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: DNTH (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 7 TIMES SQUARE, NEW YORK, NY, 10036 - **Phone**: 929-999-4055 - **Shares outstanding**: 55,934,378 as of 2026-08-03 (10-Q filed 2026-08-04) - **Former names**: Magenta Therapeutics, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000034/dnth-20260630.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000033/dnth-20260804.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000029/dnth-20260612.htm) filed 2026-06-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000026/dnth-20260521.htm) filed 2026-05-22 - [10-Q](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000022/dnth-20260331.htm) filed 2026-05-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000021/dnth-20260505.htm) filed 2026-05-05 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000012/dnth-20260409.htm) filed 2026-04-09 - [8-K](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000010/dnth-20260326.htm) filed 2026-03-26 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001690585), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Dianthus Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker DNTH, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Dianthus Therapeutics, Inc. - **Ticker**: DNTH - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US2528281080 - **Other listed symbols**: DUS:87E; FWB:87E; GETTEX:87E; LSX:A3ERZ4; MUN:87E; SWB:87E; TRADEGATE:87E; XETR:87E - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-DNTH/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/dianthus-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Dianthus Therapeutics (DNTH) news: offering", 2026-10-31, https://aibio.space/companies/dianthus-therapeutics/